This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Opal, S.M. Articles by Young, L.D. Search for Related Content PubMed Articles by Opal, S.M. Articles by Young, L.D. Social Bookmarking                         What's this?

The in vivo significance of antibiotic-induced endotoxin release in experimental Gram-negative sepsis

Divisions of infectious Diseases and Pathology, Brown University School of Medicine, and Memorial Hospital of Rhode Island, USA, Merck US Human Health Division, West Point, Pennsylvania, USA, Walter Reed Army Institute of Research, Washington DC, USA

D.L. Horn

Divisions of infectious Diseases and Pathology, Brown University School of Medicine, and Memorial Hospital of Rhode Island, USA, Merck US Human Health Division, West Point, Pennsylvania, USA, Walter Reed Army Institute of Research, Washington DC, USA

J.E. Palardy

Divisions of infectious Diseases and Pathology, Brown University School of Medicine, and Memorial Hospital of Rhode Island, USA, Merck US Human Health Division, West Point, Pennsylvania, USA, Walter Reed Army Institute of Research, Washington DC, USA

N. Parejo

Divisions of infectious Diseases and Pathology, Brown University School of Medicine, and Memorial Hospital of Rhode Island, USA, Merck US Human Health Division, West Point, Pennsylvania, USA, Walter Reed Army Institute of Research, Washington DC, USA

J. Jhung

Divisions of infectious Diseases and Pathology, Brown University School of Medicine, and Memorial Hospital of Rhode Island, USA, Merck US Human Health Division, West Point, Pennsylvania, USA, Walter Reed Army Institute of Research, Washington DC, USA

A. Bhattacharjee

Divisions of infectious Diseases and Pathology, Brown University School of Medicine, and Memorial Hospital of Rhode Island, USA, Merck US Human Health Division, West Point, Pennsylvania, USA, Walter Reed Army Institute of Research, Washington DC, USA

L.D. Young

Divisions of infectious Diseases and Pathology, Brown University School of Medicine, and Memorial Hospital of Rhode Island, USA, Merck US Human Health Division, West Point, Pennsylvania, USA, Walter Reed Army Institute of Research, Washington DC, USA

Considerable evidence now supports the experimental findings that penicillin-binding protein (PBP)-2 specific antimicrobial agents such as imipenem generate less endotoxin than PBP-3 specific agents such as ceftazidime during the process of bacteriolysis of Gram-negative bacteria. To determine if differences in endotoxin release have pathophysiologic significance in vivo, Sprague-Dawley rats were experimentally challenged with intraperitoneal injections of virulent, serum-resistant clinical strains of the following Gram-negative bacilli: Escherichia coli 018:K1, Klebsiella pneumoniae K2, and Pseudomonas aeruginosa 12.4.4 (immuno type 6). After intravenous administration of imipenem (25 mg/kg), ceftazidime (50 mg/kg) or saline control, imipenem and ceftazidime-treated animals had rapid reductions in the quantitative level of bacteremia from all three pathogens. Peritoneal fluid samples revealed spherical forms with imipenem and long, filamentous forms with ceftazidime. Circulating plasma endotoxin levels were consistently higher (P < 0.05) with ceftazidime than imipenem for 6 h after administration of E. coli or P. aeruginosa intraperitoneal challenge. Endotoxin levels were unchanged to slightly higher with imipenem than ceftazidime following K. pneumoniae intraperitoneal challenge. TNF levels peaked 2 h post-therapy and were consistently higher with ceftazidime-treated animals (P < 0.05). D-galactosamine-treated animals had LD₅₀ values that were 0.5-2 log higher (P < 0.001) with imipenem for E. coli and P. aeruginosa but did not differ from ceftazidime in animals challenged with the K. pneumoniae strain. These results indicate that the PBP-2 specific agent imipenem led to significantly less endotoxin release than did ceftazidime with its great affinity to PBP-3. Differential endotoxin release was found after antimicrobial therapy with the E. coli and P. aeruginosa strains but not with the K. pneumoniae strain tested in this study. The clinical relevance of these findings with treatment of systemic Gram-negative infections in humans will require further clinical investigation.

Journal of Endotoxin Research, Vol. 3, No. 3, 245-252 (1996)
DOI: 10.1177/096805199600300310


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?